Stock Market & Financial Investment News

News Breaks September 28, 2012 14:05 EDT DNDN, AET Dendreon climbs after Aetna says Provenge necessary for more patients Dendreon (DNDN) is advancing after Aetna (AET) indicated on its website that it would pay for additional prostate cancer patients to be treated with Dendreon's Provenge drug. Specifically, the insurer said that it now considers Provenge to be medically necessary for the treatment of adults with some forms of metastatic castrate-resistant prostate cancer. In mid-afternoon trading, Dendreon jumped 35c, or 7.56%, to $4.98. News For DNDN;AET From The Last 14 Days Check below for free stories on DNDN;AET the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 15, 2013 17:36 EDT AET Paulson gives quarterly update on stakes Subscribe for More Information May 14, 2013 12:00 EDT AET Aetna forms strategic alliance with Tawuniya Subscribe for More Information May 10, 2013 10:00 EDT DNDN On The Fly: Analyst Downgrade Summary Subscribe for More Information 09:38 EDT DNDN Active equity option families trading Subscribe for More Information 09:21 EDT DNDN On The Fly: Pre-market Movers Subscribe for More Information 07:55 EDT DNDN Dendreon may generate near-term trading opportunity, says RW Baird Subscribe for More Information 07:44 EDT DNDN Dendreon price target lowered to $1 from $5 at BofA/Merrill Subscribe for More Information 07:40 EDT DNDN Dendreon price target lowered to $6.50 from $9 at Bernstein Subscribe for More Information 05:51 EDT DNDN Dendreon downgraded to Sell from Neutral at Citigroup Subscribe for More Information May 9, 2013 14:15 EDT DNDN Dendreon downgraded to Sell from Neutral at Roth Capital Subscribe for More Information 13:32 EDT DNDN Dendreon downgraded to Sell from Hold at Stifel Subscribe for More Information 12:35 EDT DNDN On The Fly: Midday Wrap Subscribe for More Information 10:56 EDT DNDN Dendreon price target lowered to $3 from $4 at Maxim Subscribe for More Information 08:42 EDT DNDN Dendreon reports Q1 EPS (48c), consensus (48c) Subscribe for More Information May 8, 2013 08:04 EDT AET Aetna price target raised to $72 from $67 at Susquehanna Susquehanna raised its price target on Aetna following the closing of its acquisition of Coventry Health as management anticipates earnings accretion to double over the next couple of years. Near-term the firm believes the company is well positioned to exceed its 2013 guidance. Shares are Positive rated. May 7, 2013 09:36 EDT AET Aetna to host conference call Conference call to discuss agreement to acquire Coventry Health Care, Inc. will be held on May 7 at 5 pm. Webcast Link 08:59 EDT AET Aetna raises FY13 EPS view to $5.70-$5.85 from $5.50-$5.60 Subscribe for More Information 08:57 EDT AET Aetna completes acquisition of Coventry Health Aetna announced it has completed its acquisition of Coventry Health Care, a diversified managed health care company based in Bethesda, Md. "The successful completion of our acquisition of Coventry presents new opportunities for Aetna and supports our strategy for growth in the changing health care marketplace," said the company. "Together, we are well positioned - competitively, strategically and financially - to meet the evolving needs of the people we serve." May 6, 2013 12:53 EDT AET On The Fly: Midday Wrap Subscribe for More Information 06:53 EDT AET Health insurers plan to push Obamacare, Politico says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.